Takeda Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Takeda Pharmaceutical şirketinin toplam hissedar öz sermayesi ¥6,921.6B ve toplam borcu ¥5,051.2B olup, bu da borç-öz sermaye oranını 73% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥14,573.0B ve ¥7,651.4B dir. Takeda Pharmaceutical 'in FAVÖK'ü ¥653.6B faiz karşılama oranı 6.7 dur. Şirketin ¥859.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

73.0%

Borç/özkaynak oranı

JP¥5.05t

Borç

Faiz karşılama oranı	6.7x
Nakit	JP¥859.02b
Eşitlik	JP¥6.92t
Toplam yükümlülükler	JP¥7.65t
Toplam varlıklar	JP¥14.57t

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TKD 'nin kısa vadeli varlıkları ( ¥3,054.0B ) kısa vadeli yükümlülüklerini ( ¥2,387.2B ) aşıyor.

Uzun Vadeli Yükümlülükler: TKD 'un kısa vadeli varlıkları ( ¥3,054.0B ) uzun vadeli yükümlülüklerini ( ¥5,264.2B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TKD 'nin net borç/öz sermaye oranı ( 60.6% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: TKD 'nin borç/öz sermaye oranı son 5 yılda 103.2% seviyesinden 73% seviyesine düştü.

Borç Kapsamı: TKD 'nin borcu işletme nakit akışı ( 17.3% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: TKD 'in borcuna ilişkin faiz ödemeleri EBIT ( 6.7 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Takeda Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2025 earnings released: EPS: JP¥58.15 (vs JP¥30.68 loss in 2Q 2024)

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Upcoming dividend of JP¥98.00 per share

Takeda Receives European Commission Approval for ADZYNMA®

First quarter 2025 earnings released: EPS: JP¥60.71 (vs JP¥57.51 in 1Q 2024)

Final dividend of JP¥98.00 announced

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Full year 2024 earnings released: EPS: JP¥92.09 (vs JP¥204 in FY 2023)

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Full year 2024 earnings released: EPS: JP¥92.09 (vs JP¥204 in FY 2023)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Upcoming dividend of JP¥94.00 per share

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Third quarter 2024 earnings released: EPS: JP¥67.38 (vs JP¥76.63 in 3Q 2023)

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings released: JP¥30.68 loss per share (vs JP¥39.77 profit in 2Q 2023)

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Upcoming dividend of JP¥94.00 per share at 3.9% yield

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: JP¥204 (vs JP¥147 in FY 2022)

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin